Sunshine Biopharma Inc. (SBFM) 2025 Annual Report: Key Insights for Investors

Executive Summary

Sunshine Biopharma Inc. (“Sunshine” or “the Company”) has released its 2025 Form 10-K, providing shareholders and the market comprehensive insights into the company’s operations, financial condition, risks, and governance. The report contains several critical disclosures that could significantly impact the share price and investor sentiment.

Key Highlights

• Net Losses Continue: Sunshine Biopharma incurred a net loss of \$5,975,352 for the year ended December 31, 2025, compared to a net loss of \$5,134,116 for 2024. The company states it has an accumulated deficit and may never achieve profitability. This ongoing deficit is a crucial concern for shareholders and could affect share value.
• Cash Position & Capital Raises: As of December 31, 2025, the company had cash and cash equivalents totaling \$9,123,308. Sunshine raised an aggregate of \$6,478,624 from warrant exercises in 2024 and 2025, and received \$1,828,596 from a registered direct offering in April 2025. The company also issued 660,000 shares on warrant exercise (\$1,840,014) and 350,000 shares for \$724,500. Liquidity remains strong but is dependent on external capital raises.
• Public Float & Shares Outstanding: As of June 30, 2025, the aggregate market value of voting and non-voting common equity held by non-affiliates was \$7,061,719. As of April 2, 2026, there were 4,905,945 shares of common stock outstanding.
• Nasdaq Listing Risks: The company’s shares traded slightly above \$1.00, the minimum Nasdaq bid price. Sunshine has shareholder approval for a reverse stock split (up to 1-for-10), but there’s no assurance the company will maintain compliance with Nasdaq listing requirements. Delisting would negatively affect liquidity, financing, and the ability to offer equity incentives.
• No Dividends Planned: Sunshine has not paid dividends since incorporation and does not anticipate paying dividends in the foreseeable future. Earnings are expected to be retained for expansion and business plan implementation.
• Potential Shareholder Dilution: The board can issue up to 30 million preferred shares without further shareholder approval. 130,000 Series B Preferred shares are outstanding, held by the CEO. Additionally, 15,227,962 Series B Warrants are outstanding, each exercisable for one common share at \$2.07, plus 482 tradable warrants at \$220.00. Future capital raises may dilute existing shareholders.

Risks & Price Sensitive Information

• Profitability Concerns: The company warns it may never achieve profitability, and future funding needs are uncertain. If additional financing is unavailable or unfavorable, Sunshine may need to scale back operations, reduce workforce, or license out products.
• Executive Dependence: Sunshine relies heavily on Dr. Steve N. Slilaty for strategic management and scientific direction. His departure would significantly delay or prevent achieving business objectives.
• Product Acceptance & Market Risk: Even if proprietary drug candidates are approved, profitability depends on market acceptance, physician and payer uptake, pricing, and insurance listing. Failure in any of these areas would materially impact the business.
• Raw Material & Supply Chain Risks: The company faces risks from suppliers, including quality, cost increases, and production interruptions due to pandemics, weather, strikes, geopolitics, and disasters.
• Adverse Publicity: Negative press or regulatory actions (e.g., FDA Form 483, warning letters) could materially affect sales and revenues, especially if products are alleged or proved harmful.
• Cybersecurity & Data Protection: Sunshine invests in advanced cybersecurity technology and reports no material incidents in 2025. However, cyber risks remain a concern, and any future breach could impact operations and reputation.
• Share Price Volatility: Shares have historically been volatile. If trading volume decreases or Nasdaq requirements are not met, liquidity and price could be negatively affected.
• Equity Incentive Plan: 683,000 shares remain available for issuance under the 2023 Equity Incentive Plan. No options or SARs were granted to executives proximate to MNPI (material non-public information) releases, but future grants could be price sensitive.
• Critical Accounting Estimates: The company’s financial statements are based on estimates and assumptions, particularly around revenue recognition and commission transactions. Any change or error in these areas could affect reported financials.

Governance & Compliance

• Non-Accelerated Filer & Smaller Reporting Company: Sunshine is classified as both, meaning reduced reporting requirements but potentially less transparency for investors.
• No Mine Safety Disclosures: Not applicable for this company.
• Controls & Procedures: No auditor attestation of internal controls under Sarbanes-Oxley 404(b). The company is not required to file such a report.
• No Off-Balance Sheet Arrangements: The company confirms none exist as of year-end.

Product Pipeline & Subsidiaries

• Proprietary Drugs: Sunshine is developing K1.1 mRNA-based anticancer therapy and SBFM-PL4 for SARS Coronavirus. Approval and commercialization of these products are crucial for future growth but remain uncertain.
• Generic Pharmaceuticals: Nora Pharma, a subsidiary, faces risks from launch delays, operational readiness, and patent litigation. Unsuccessful launches or regulatory approval delays could materially affect projected sales.
• Sunshine Biopharma Canada Inc.: Wholly owned subsidiary serving Canadian operations, subject to Health Canada regulatory requirements.

Audit Opinion

Independent auditors M&K CPAS, PLLC issued an unqualified opinion for 2025, stating financial statements present fairly the financial position and results in accordance with U.S. GAAP. The critical audit matter identified relates to revenue recognition, specifically commission transactions and third-party sales data. There were no restatements or error corrections requiring compensation recovery analysis.

Conclusion for Investors

Sunshine Biopharma’s 2025 Annual Report reveals ongoing losses, heavy dependence on external capital, and significant risks around Nasdaq compliance, dilution, and executive retention. The company’s ability to achieve profitability, maintain listing, and successfully commercialize its drug candidates remains uncertain. These factors are highly price sensitive and could materially affect the share price.

Investors should closely monitor developments regarding capital raises, executive retention, Nasdaq compliance, product approvals, and market acceptance. Any change in these areas could trigger substantial share price movement, either positive or negative.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with professional advisors before making any investment decisions. The information summarized herein is based on the company’s official filings and may be subject to change. Past performance is not indicative of future results.

View Sunshine Biopharma Inc. Historical chart here